Author:
Zhang Jingxia,Li Shasha,Zhao Chongbo,Wang Weifeng,Li Fan,Li Fang
Funder
National Natural Science Foundation of China
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference9 articles.
1. The clinical benefits of Chinese patent medicines against COVID-19 based on current evidence;Zhang;J Pharm Res,2020
2. The randomized controlled study of Lianhua Qingwen capsule in treating A/H1N1 influenza;Liu;Chin J Diff Complicat Cases,2011
3. Clinical observation of Jinhua Qinggan granule in treating pneumonia infected by new c;Duan;J Tradit Chin Med,2020
4. Efficacy and safety of Chinese patent medicine injection for COVID-19: a protocol for systematic review and meta-analysis;Lu;Medicine (Baltimore),2020
5. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation;Shamseer;BMJ (Clinical research ed),2015
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献